CACNA2D1
Voltage-dependent calcium channel subunit alpha-2/delta-1
As of the edition of 20 October 2026, CACNA2D1 (voltage-dependent calcium channel subunit alpha-2/delta-1, UniProt P54289) has 5 drugs tested at it and 14 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P54289
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 30
- Disease areas
- Nervous system; Mental health; Bones, joints and muscles; Hormones; Cancer; Chemically induced; Urinary and reproductive; Injuries
- Registered trials of its drugs
- 637
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Status not established | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pregabalin | Marketed | Phase 4 | none listed |
| Gabapentin | Marketed | Phase 4 | none listed |
| Gabapentin enacarbil | Marketed | Phase 4 | Ends 2026 |
| Mirogabalin | Active | Phase 4 | none listed |
| YHD1119 | Status not established | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 5 |
| Undetermined | 5 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Astellas | Route B |
| Azurity Pharmaceuticals | Route B |
| Aché Laboratórios Farmacêuticos | Route B |
The other 11 companies at CACNA2D1
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at CACNA2D1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.